Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer
Background: Ovarian cancer (OvCa) constitutes a rare and highly aggressive malignancy and is one of the most lethal of all gynaecologic neoplasms. Due to chemotherapy resistance and treatment limitations because of side effects, OvCa is still not sufficiently treatable. Hence, new drugs for OvCa the...
Guardado en:
Autores principales: | Inken Flörkemeier, Tamara N. Steinhauer, Nina Hedemann, Magnus Ölander, Per Artursson, Bernd Clement, Dirk O. Bauerschlag |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8b89334405764c299bc1e0e335c0f7dc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer
por: Christoph Rogmans, et al.
Publicado: (2021) -
Dual role of topoisomerase II in centromere resolution and aurora B activity.
por: Paula A Coelho, et al.
Publicado: (2008) -
A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
por: Zhi-Ying Li, et al.
Publicado: (2021) -
Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum.
por: Wilian A Cortopassi, et al.
Publicado: (2014) -
Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion
por: Priya Luthra, et al.
Publicado: (2017)